Additionally, a recently published clinical trial combining PARPi and androgen receptor (AR)‐directed therapy in patients with advanced PCa demonstrated clinical benefit, irrespective of HR status (Clarke et al, 2018). The gene discussed is AR; the disease is posterior cortical atrophy.